2022-10-27
Interim report third quarter, January 1 – September 30, 2022, Kancera ab (publ.), org.nr. 556806-8851
This is a translation of the interim report published in Swedish at October 26, 2022
Read More
2022-10-27
Kancera reports new preclinical results supporting potential for its ROR1 inhibitor in B-cell malignancies
Kancera AB (publ) reports new preclinical results supporting the potential for KAN571, a ROR1 inhibitor, for treatment of mantle cell lymphoma (MCL), a subtype of B-cell malignancies. Preclinical studies of KAN571 in MCL cell lines show that KAN571 effectively...
Read More
2022-10-20
Kancera reports promising preclinical results from studies of its Fractalkine axis blocking drug candidates in B-cell lymphoma
Kancera AB (publ) reports new preclinical results supporting the potential for the company’s Fractalkine axis blocking candidate drugs to increase the efficacy of standard-of-care drug treatment of B-cell lymphomas, such as chronic lymphocytic leukemia (CLL).
Read More
2022-09-27
Kancera reports good progress of recruitment in ongoing phase IIa study of KAND567 in myocardial infarction and the decision to allow for recruitment of additional patients
Kancera AB (publ) is today reporting that patient recruitment to the ongoing phase IIa study of KAND567 in myocardial infarction patients is progressing well and 54 patients of the targeted 60 patients have been enrolled so far. The company...
Read More
2022-09-22
Kancera reports convincing preclinical results and decision to initiate clinical development of KAND567 in ovarian cancer
Kancera AB (publ) is today reporting new results that confirm that the company’s Fractalkine-blocking candidate drug may increase the efficacy of platinum-based chemotherapy and reduce tumor growth in animal models of ovarian cancer. As a result, Kancera has met...
Read More
2022-08-22
Interim report second quarter, January 1 – June 30, 2022, Kancera ab (publ.), org.nr. 556806-8851
This is a translation of the interim report published in swedish on Januaryt 19th
Read More
2022-07-29
Correction: Interim report first quarter 2022, 1 January – 31 March 2022 Kancera AB (publ.), org.nr. 556806-8851
Due to technical reasons this report was only published as a press release, but did not show up in the Finacial reports section on the Kancera web page. This is now corrected. First quarter in brief January – MarchFinancial...
Read More
2022-05-25
Kancera receives patent grant in US for the drug candidate KAND145
Kancera AB announces today that the US Patent Office (USPTO) has issued a patent that protects the chemical structure of Kancera's fractalkine blocker KAND145. This patent, US 11,339,183, is owned by Kancera and is valid through 2039.
Read More
2022-05-23
Kancera provides operational update in connection with the interim report for the first quarter of 2022
This is a translation of a press release published in Swedish by Kancera AB (publ) on May 20, 2022.
Read More
2022-05-20
Interim report first quarter 2022, 1 January – 31 March 2022 Kancera AB (publ.), org.nr. 556806-8851
First quarter in brief January – MarchFinancial summary for the first quarter and the period January – March 2022· Net sales amounted to SEK 0 million (SEK 0.0 million).· R&D costs amounted to SEK 10,6 million (8,2 million).· Operating...
Read More